Glioblastoma Clinical Trials in Chicago, Illinois

8 studies are recruiting for glioblastoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

   The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   56 in total

   Run by

   CarThera

   See if you can join NCT05902169 on ClinicalTrials.gov

2. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

3. EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Gliobla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   102 in total

   Run by

   NovoCure GmbH

   See if you can join NCT06556563 on ClinicalTrials.gov

4. A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

   This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high gra…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern Medicine, Chicago, Illinois

   Locations

   3 in total

   Run by

   Tetragon Biosciences Ltd

   See if you can join NCT07464925 on ClinicalTrials.gov

5. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

   The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

   Locations

   18 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT06333899 on ClinicalTrials.gov

6. Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

   A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University Robert H Lurie Medical Research, Chicago, Illinois

   Locations

   8 in total

   Run by

   Orano Med Theranostics, SAS

   See if you can join NCT05283330 on ClinicalTrials.gov

7. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

   The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

   Stage

   Phase 2

   Ages

   1 to 39

   Site

   Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

   Locations

   20 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05843253 on ClinicalTrials.gov

8. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Chicago, Illinois

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov